One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
Authors' conclusion
Distinct clinical and biochemical characteristics are associated with poor adherence versus discontinuation. Understanding these patterns is crucial for developing targeted strategies to improve sustained use, ultimately enhancing treatment outcomes for people with type 2 diabetes.
Study context
- Population
- Individuals with T2D initiating an SGLT2i or GLP-1 RA, Scottish Care Information Diabetes Collaboration database
- Exposure
- Usage patterns of SGLT2i and GLP-1 RA subclasses; characteristics associated with each usage category
- Outcome
- Usage category: adherent, poor adherence or three discontinuation categories including a proxy for intolerance
- Follow-up
- 1 year
Methodological detailselectronic health records, real-world
- Electronic health records
- Real-world
Main finding
As reported in the abstract
- SGLT2i: poor adherence more common in younger individuals, with greater socioeconomic deprivation and higher HbA1c
- SGLT2i: intolerance more frequent in older, leaner females and in those with prior genital thrush
- GLP-1RA: newer agents associated with more favourable usage patterns
- GLP-1RA: poor adherence more frequent with liraglutide, lixisenatide and exenatide vs semaglutide; intolerance more common with lixisenatide
- GLP-1RA: poor adherence associated with younger age and prior GLP-1RA use; intolerance with lower BMI, female sex and more advanced CKD
Observational data: associations, not effects.
Original publication
One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population. Diabetes Obes Metab. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →